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Kava is traditionally consumed by South Paciﬁc islanders as a drink and became popular in Western society as a supplement
for anxiety and insomnia. Kava extracts are generally well tolerated, but reports of hepatotoxicity necessitated an international
reappraisal of its safety. Hepatotoxicity can occur as an acute, severe form or a chronic, mild form. Inﬂammation appears to be
involved in both forms and may result from activation of liver macrophages (Kupﬀer cells), either directly or via kava metabolites.
Pharmacogenomics may inﬂuence the severity of this inﬂammatory response.
1.Introduction
Kava (Piper methysticum Frost F.) is a perennial plant which
has been used for centuries by South Paciﬁc communities
for medicinal, social, and cultural purposes. Traditionally,
the rhizome of the plant is macerated with water or coconut
milk to produce a beverage with relaxant and psychoactive
properties [1]. In the 20th century, it became popular in
the Western world as a herbal supplement for anxiety and
insomnia.
2.Chemistry andToxicology of Kava
More than 40 compounds have been isolated from kava,
with the active components present in the lipid-soluble resin
containing three chemical classes (i) arylethylene-α-pyrones,
(ii) chalcones and other ﬂavones, and (iii) conjugated diene
ketones. It is the substituted 4-methoxy-5, 6-dihydro-α-
pyrones or kavapyrones commonly known as kavalactones
that possess the highest anxiolytic eﬀects [2].
Total kavalactone accounts for 3%–20% dry weight, with
the highest concentration in the lateral roots, decreasing
gradually towards the aerial plant structures. To date, eigh-
teen kavalactones have been identiﬁed from the root, six of
which account for approximately 95% of the organic extract
namely, kavain, dihydrokavain, methysticin, dihydromethys-
ticin, yangonin, and desmethoxyyangonin (Figure 1). When
these kavalactones are eluted from a sample of kava by
HPLC and sorted by decreasing order of quantity, the
chemical signature obtained distinguishes individual strains
(cultivars).Suchchemotypinghasidentiﬁedover200variant
strains of kava, but the chemical signature can vary between
roots, rhizomes, and basal stems [3]. Root and leaf extracts
from four Hawaiian cultivars (Mahakea, PNG, Purple Moi,
andNene)foundthatdihydrokavainanddihydromethysticin
comprised more than 70% of the total kavalactones in leaves,
whereas each of the six major kavalactones represented
around 10% to 20% of the total kavalactones in root extracts
[4].
Whilst kava extracts are generally well tolerated, toxic
doses were determined in vivo using animal studies and
in vitro.T h eL D 50 (mg/kg) for kavain, methysticin, dihy-
drokavain, and dihydromethysticin in mice ranges from 41–
69 (intravenous), 325–530 (intraperitoneal), and 920–1130
(oral) [2]. F344 rats treated with 2g/kg/day kava extracts
in corn oil by oral gavage ﬁve days a week for fourteen
weeks exhibited elevations in γ-glutamyl transferase (GGT),
serum cholesterol, protein, and albumin levels, along with
hypoglycaemia, within days of treatment [5]. Cytotoxicity
associated with kavalactones was demonstrated for human
hepatocytes in vitro (EC50 values approximately 50μM) [6]
and neurones in vivo at ≥300μM[ 7], and apoptosis is the
mechanism of cell death [8]. Since the highest serum kavain
concentrationrecordedinahumanis17.4μM[9],thesedata
suggest that for most individuals, kavalactones have a wide
therapeutic index.2 Advances in Pharmacological Sciences
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1. Kavain
3. Methysticin
5. Yangonin
7. Pipermethystine
6. Desmethoxyyangonin
8. Flavokavain B
2. 7, 8-Dihydrokavain
4. 7, 8-Dihydromethysticin
Figure 1: Structures of the six main kavalactones (1–6), Pipermethysticine (7), and Flavokavain B (8). The chemical formulae are
kavain (C14H14O3), 7,8-dihydrokavain (C14H16O3), methysticin (C15H14O5), 7,8-dihydromethysticin (C15H16O5), yangonin (C15H14O4),
desmethoxyyangonin (= 5,6-dehydrokavain = C14H12O3), pipermethystine (C16H17NO4), and ﬂavokavain B (C17H16O4).
Pipermethysticine (PM) is a toxic alkaloid present in
kava leaves and stem peelings, which can contaminate
kava products during high production and/or poor quality
control [10]. HepG2 human hepatoma cells exposed to
100μM PM for 24 hours showed 90% loss of cell viability,
with 65% loss of viability with 50μM PM due to disruption
of mitochondrial function and consequent apoptosis [11].
Fischer-334 rats given 10mg/kg PM daily by oral gavage
for two weeks demonstrated adaptive changes to oxidative
stresssuchasasigniﬁcantincreaseinhepaticglutathioneand
cytosolic superoxide dismutase (Cu/ZnSOD) [12]. Thus, PM
is a potential cause of kava hepatotoxicity although it was
not detected in any samples in a recent study using products
available on the German market [13].
Flavokavain B is a cytotoxic component of kava root and
is present in aqueous and organic extracts [14]. The highest
yields are in chloroform extracts, followed by acetone then
hexane fractions [15]. Hepatocellular toxicity results from
mitogen-activated protein kinase (MAPK) signalling leading
to oxidative stress and apoptosis [16]. Due to its location in
the plant root, ﬂavokavain B is likely to be present in both
traditional and pharmaceutical preparations of kava.
The chemical content of kava products and hence
potential for adverse eﬀects vary according to plant age, part
used, cultivar, geographical location, and growth conditions.
In the Kava Act 2002 [17] the government of Vanuatu
classiﬁed the diﬀerent cultivars of kava as noble (traditional
social beverage with long history of safe use), medicinalAdvances in Pharmacological Sciences 3
(used for speciﬁc therapeutic eﬀects), two days (can cause
strong side eﬀects such as nausea due to high levels of the
kavalactonedihydromethysticinandbannedforexport), and
wichmannii (which also induce strong side eﬀects and are
banned from export) [18].
Emphasis on the links between method of preparation
and toxicity has declined recently. This is due to reports
identifying adverse eﬀects in patients using either ethano-
lic/acetonic kava extracts or traditional aqueous extracts,
suggesting that toxicity is more dependent on the kava plant
itself than the extraction solvent(s) used [19].
3.AdverseEffects ofKava
Meta-analyses of placebo-controlled studies showed a sig-
niﬁcant reduction in anxiety for patients receiving kava
extract compared with patients receiving placebo [20, 21].
The most common treatment regime used was 300mg/day
for four weeks. A study using a similar dose (280mg/day for
four weeks) found no diﬀerence between kava extract and
placebo in terms of occurrence of adverse events, withdrawal
symptoms, eﬀect on heart rate, blood pressure, laboratory
assessments, and sexual function, which supports the safety
o ft h i sp r o t o c o l[ 22].
However, two post-marketing trials in Germany (n >
3000) showed a small dose-dependent increase in adverse
eﬀects caused by kava extracts [23]. Risk factors for adverse
reactions include chronic, heavy use and concurrent use with
other drugs, herbs, and dietary supplements [24, 25].
Side eﬀects of kava consumption include skin reactions
and central nervous system eﬀects. Kava dermopathy has
been well documented among Paciﬁc Islanders [26] and is
a reversible condition characterised by dry scaly yellow skin
covering the palms of the hands, soles of the feet, and back
[27]. It is speculated to have a link to cholesterol metabolism
and hepatotoxicity due to the presence of jaundice [28].
Short-term kava use can produce extrapyramidal side eﬀects
resulting in oral dyskinesia and serious exacerbations of
parkinsonism-like symptoms, while heavy use may pre-
dispose individuals to seizures [27]. However, a double-
blind placebo controlled trial showed kava has no eﬀect on
motor vehicle performance. In another study, no statistically
signiﬁcant diﬀerence between kava and placebo was present
in participants performing tracking tasks [27].
The most serious adverse reaction associated with kava is
hepatotoxicity. Reports of kava hepatotoxicity ﬁrst emerged
in Germany in 1998, and by the end of 2005, the World
Health Organisation had received 91 reports of 189 adverse
reactions relating to kava-only products. Fiftly-ﬁve of those
reactions involved liver and biliary system disorders, includ-
ing three cases of hepatic failure and two cases of hepatic
comas [29]. Reported daily doses ranged from 45–1200mg
kavalactones taken for one week to twelve months [25].
4. Metabolism of Kavalactones
The main metabolic pathways for kavalactones in humans
and rats are hydroxylation of the C-12 in the aromatic
ring, breaking and hydroxylation of the lactone ring with
subsequent dehydration, reduction of the 7,8-double bond,
and demethylation of the 4-methoxyl group [30–32]. Prod-
ucts of kavain metabolism found in human serum and urine
include p-hydroxykavain, p-hydroxy-5,6-dehydrokavain,
p-hydroxy-7,8-dihydrokavain, 5,6-dehydrokavain, 6-phenyl-
5-hexen-2,4-dione [33], and 6-phenyl-3-hexen-2-one [34].
Human metabolites identiﬁed for other kavalactones include
11,12-dihydroxykavain-o-quinone for methysticin, 11,12-
dihydroxy-7,8-dihydrokavain-o-quinone for7,8-dihydrome-
thysticin and 12-desmethylyangonin either from demeth-
ylation of the 12-methoxyl group of yangonin or hydroxy-
lation at C-12 of desmethoxyyangonin [30, 35]. In rats,
approximately 50% to 75% of administered kavalactones are
excreted in the urine, mostly as glucuronide and sulphate
conjugates. Approximately 15% is excreted in the bile
[30, 32, 36]. Reactive kava metabolites may potentially
alkylate DNA or disrupt enzymatic and metabolic activity,
inducing hepatotoxicity.
5.Mechanismof KavaHepatotoxicity
Despite the evidence for liver damage and inﬂammation
in animals and humans treated with kava, clinical cases
of hepatotoxicity amongst indigenous users caused by
traditional aqueous root extracts are limited to two cases
in New Caledonia [37]. The dose of kavalactones in one
patient was 18 grams per week for four to ﬁve weeks and was
unknown in the other. Clinical surveillance in the Northern
Territory, Australia over 20 years has not documented any
cases of fulminant hepatic failure attributable to kava,
despite doses estimated to be 10–50 times the recommended
therapeutic doses.
Based on these observations, most hepatic eﬀects of
kava appear to be reversible or can be compensated for.
Hence, pharmacogenomic eﬀects may be involved in the
most severe cases of toxicity. For example, the hydroxylation
of the aromatic ring and demethylation of kavalactones is a
function of CYP2D6 enzymes [30]. Four human phenotypes
for CYP2D6 activity (ultrarapid, eﬃcient, intermediate, and
poor) are deﬁned according to debrisoquine metabolism.
The two Europeans with kava-related hepatotoxicity were
phenotyped as poor metabolisers according to CYP2D6
activity [38]. It is known that 12%–21% of Caucasians
are poor metabolisers compared to less than 1% for
Asians/Paciﬁc Islanders, which may contribute to the lower
incidence of kava hepatotoxicity in the Paciﬁc [39]. Cau-
casians also have a higher frequency of ultrarapid metabolis-
ers compared to Asians/Paciﬁc Islanders (1% to 5% versus
0% to 2%). These individuals could experience adverse
reactions following a burst of reactive kava metabolites.
Acute kava hepatotoxicity involves inﬂammation.
Histopathology results from a 50-year-old man [40]a n d
a 33-year-old woman [38] displaying hepatic symptoms
following use of kava supplements showed extensive, severe
hepatocellular necrosis and inﬁltration with lymphocytes,
eosinophils, and activated macrophages. Experimental
studies with kavain-perfused rat livers examined via electron
microscopy displayed a disruption of hepatic vasculature
with narrowing of blood vessels, constriction of sinusoidal4 Advances in Pharmacological Sciences
blood vessels, and retraction of the endothelium compared
to controls [41]. Liver macrophages (Kupﬀer cells) within
the sinusoids of the kavain-perfused liver also appeared
swollen with large cytoplasmic vacuoles and phagocytosed
material.
Subclinical liver abnormalities occurred in clinical
studies with chronic, indigenous, kava users. A study with
Australian aborigines in the Northern Territory revealed
elevations in γ-glutamyl transferase (GGT) and alkaline
phosphatase (ALP) in 61% and 50%, respectively, of
participants who reported using kava at least once in the
month prior to the measurement, compared to less recent
users and nonusers [42]. These enzymes return to normal
after one to two months of abstinence [43]. There were no
diﬀerences between the groups in ALT, bilirubin, albumin,
or total protein. Unlike the German clinical trials for anxiety,
kava consumption was not regulated in these studies, and
the median duration of kava use was twelve years, with a
range from one to eighteen years.
Similar results were observed in a predominantly Tongan
population in Hawaii, which compared liver function tests
between 31 healthy adult kava beverage drinkers and 31
healthy adult nonkava beverage drinkers [44]. GGT was
signiﬁcantly elevated in 65% of the kava drinkers versus
26% in the controls, and ALP was signiﬁcantly elevated in
23% of kava drinkers versus 3% in the controls. There was
no signiﬁcant diﬀerence in ALT, AST, bilirubin, albumin,
or total protein. Increases in GGT and ALP without ALT
or AST elevation are suggestive of cholestasis rather than
hepatocellular damage.
Cholestasis can be due to either defective bile formation
in hepatocytes or disruption to bile secretion and ﬂow
within bile ducts [45]. Mechanisms of noninﬂammatory
cholestasis include inhibition of cellular proteins and
transporters. Direct or indirect activation of Kupﬀer cells
and their subsequent release of pro-inﬂammatory cytokines,
growth factors, and reactive oxygen species is a cause of
inﬂammatory cholestasis, which may involve hepatocytes
or bile ducts [46]. In the absence of hyperbilirubinaemia,
elevations in GGT and ALP are more likely to be due to bile
duct inﬂammation. Each of these mechanisms could be pre-
cipitated by kava extracts and are possible explanations for
the cholestasis observed in chronic, indigenous, kava users.
Hence, Kupﬀer cells could be involved in both acute and
chronic kava hepatotoxicity. These cells are also implicated
in the pathogenesis of many other liver conditions, including
ﬁbrosis,viralhepatitis,steatohepatitis,alcoholicliverdisease,
andactivationorrejectionoftheliverduringtransplantation
[47, 48]. In animal studies, depletion of the Kupﬀer cell
population is hepatoprotective during ischemia repurfusion
injury [49], sepsis [50, 51], radiotherapy [52], and diet-
induced steatosis and insulin resistance [53]. Kupﬀer cell
depletion experiments could be a valuable tool for determin-
ing their role in kava hepatotoxicity.
6. Additional Studies
Furthur studies could investigate the extent of kavalactone
metabolisminhumansandtheproportionsofurinaryversus
biliary excretion of kavalactones and their metabolites at
diﬀerent time points after ingestion. Such studies would
further deﬁne normal kavalactone metabolism, suggest tar-
get cytochrome P450 enzymes for pharmacokinetic herb-
drug interactions with kavalactones, and aid the identiﬁca-
tion of toxic metabolite(s) and their contribution to kava
hepatotoxicity. Similar animal studies could be conducted
with the alkaloid Pipermethysticine and the chalcone Fla-
vokavain B. CYP450 proﬁling of individuals involved in such
studies could clarify pharmacogenomic diﬀerences in kava
metabolism and could be performed either genotypically
or phenotypically using substrates such as debrisoquine for
CYP2D6 in humans [54].
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